Skip to content

Biomarkers for Predicting Mortality in Patients With Suspected Sepsis

The Use of Biomarkers for Predicting Mortality in Patients With Suspected Sepsis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07521306
Enrollment
250
Registered
2026-04-09
Start date
2023-05-01
Completion date
2024-08-01
Last updated
2026-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biomarkers, Mortality, Sepsis

Keywords

Sepsis biomarkers, Mortality

Brief summary

This retrospective study aimes to analyze the association of a number of routinely performed biomarkers with mortality in patients admitted to ICU with suspected sepsis. The study includes patients \>18 years of age, who had been admitted to the ICU with suspected sepsis. At ICU admission, baseline levels of PCT, CRP, albumin and lactate as well as WBC, neutrophil and lymphocyte counts will recorded.

Detailed description

This study aimes to investigate the association of a number of biomarkers with 28-day mortality of patients admitted to the ICU with suspected sepsis, which included C-reactive protein (CRP), procalcitonin (PCT), WBC count, neutrophil count, lymphocyte count, albumin and lactate. Data will obtained from hospital electronic medical records. Data includes age, sex, duration of ICU stay, origin of infection (urinary, abdominal, pulmonary, soft tissue, central nervous system, catheter-related, mixed, others) and comorbidities (hypertension, diabetes mellitus, chronic obstructive pulmonary disease, chronic renal failure, heart failure, coronary artery disease, malignancies, others). Whether patients were admitted to the ICU following a scheduled surgery or emergency surgery will also recorded. At admission, baseline levels of PCT, CRP, albumin and lactate as well as WBC, neutrophil and lymphocyte counts will recorded. The primary outcome is 28-day mortality. For patients with multiple episodes requiring ICU admission, only the most recent episode will taken into consideration.

Interventions

None listed

Sponsors

Antalya Training and Research Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \>18 years of age * admission to the ICU with suspected sepsis

Exclusion criteria

* ICU admission following cardiopulmonary resuscitation or cardiac surgery * Having a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection * Interruption of the treatment process because of transfer to another healthcare facility

Design outcomes

Primary

MeasureTime frameDescription
28-day mortality28 daysmortality within 28 days after intensive care admission

Countries

Turkey (Türkiye)

Contacts

PRINCIPAL_INVESTIGATORSümeyye Uğur

Antalya Training and Research Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 10, 2026